 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...1920212223242526272829...3637» |
- |||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Lung adenoca with brain mets at presentation- Complete metab response to Alectinib in just 4 months . Why waste Lorlatinib upfront ? @PatelOncology @JackWestMD @StephenVLiu @drgandara @DrSteveMartin @SewantiLimaye @christine_lovly @Jbauml @AndresFCardonaZ @notahedge (Twitter) - Dec 21, 2020
- ||||| Alecensa (alectinib) / Roche
Clinical: I have one such patient with cT4N0 ALK+ adeno to whom we gave neoadj alectinib during the spring wave of #COVID19 pandemic. Went on to have VATS lobe after a nice response. Home POD#1 and now in surveillance. #LCSM #TSSMN wish we had funding to continue adjuvant targeted therapy. (Twitter) - Dec 19, 2020
- ||| Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical, Adverse events: Alectinib followed by lorlatinib or brigatinib followed by lorlatinib both options now. Different side-effects/ number of tablets to take. Can switch from one to the other within 1st 3 months if troublesome toxicity. Choice should be guided by discussion with patient. (Twitter) - Dec 19, 2020
- || Alecensa (alectinib) / Roche
I have no doubt that Alectinib or why not Selpe-praseltinib very effective here at least for DFS, not sure on OS. Would I offer any of them now without evidence? No. Whoever thinks yes should explain to then why they are trial ongoing and how long would he/she offer that 4 (Twitter) - Dec 19, 2020
- ||||| Alecensa (alectinib) / Roche
Clinical: Early on OS curves in FLAURA and ALEX are overlapping, and arguably longer term data suggests alectinib may be MORE effective in ALK+ NSCLC than osi in EGFR+. So yes, I think you have to consider highly effective TKIs in adjuvant oncogene-driven NSCLC. #LCSM (Twitter) - Dec 18, 2020
- ||||| Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: Seems like a step backwards to do PCR in 2020. And between you and me (rest of Twitter please stop reading) - if you have a patient with resected stage III NSCLC with an ALK fusion - would you at least discuss adjuvant brigatinib or alectinib? (Twitter) - Dec 18, 2020
- || Lorbrena (lorlatinib) / Pfizer
Clinical, Journal: Lorlatinib in previously-treated ALK-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. (Pubmed Central) - Dec 18, 2020
P2
Lorlatinib showed clinically meaningful responses and IC-responses among ALK-rearranged Japanese patients with NSCLC who received ≥1 prior ALK TKI, including meaningful responses among those receiving prior alectinib only. Lorlatinib was generally well tolerated.
- [VIRTUAL] Evolving Challenges in Drug Development (Scientific Program Auditorium) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1872;
The targeted agents approved in 2020 for patients with lung cancer include selpercatinib and pralsetinib for those with RET rearrangements and capmatinib for those with MET exon 14 skip mutations...The ongoing revolution in the evaluation and treatment of patients with lung cancer continue to define rare patient subsets who can be effectively treated with different agents. The task of identifying these patients remain a logistical challenge and the ability of our patients and our health care systems to support the costs of these therapies will continue to tax our system.
- Alecensa (alectinib) / Roche
[VIRTUAL] Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST) (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1609;
P2/3
Due to the low rate of DLTs seen in patients treated with alectinib 900mg BID, escalation to 1,200mg BID could have occurred if the study continued. Due to the nature of this study, limited efficacy, safety and PK data were collected.
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
[VIRTUAL] Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1569;
Conclusion This case suggests that alectinib, even belonging to the same drug class, could be used as an alternative agent when crizotinib is the etiology of the liver damage. While evidence from clinical trials are scarce, experiences like that, in a real-world scenario, may add in clinical decision.
- Alecensa (alectinib) / Roche
[VIRTUAL] VATS Right Upper Lobectomy for Advanced Non-Small Cell Lung Cancer After ALK-Tyrosine Kinase Inhibitor Administration. (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1567;
Alectinib was continued after the operation, and chest CT shows no sign of recurrence so far. Conclusion We experienced a VATS right upper lobectomy for advanced non-small cell lung cancer after ALK-tyrosine kinase inhibitor administration.
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
[VIRTUAL] A Review of Clinical Outcomes of Irish Patients With ALK Rearranged NSCLC (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1566;
Crizotinib-led sequences were most common, reflecting the approval history of ALK inhibitors in Ireland during the study period. In this real-world experience, there were more treatment discontinuations and dose reductions of TKIs than the phase 3 clinical trials that led to their approval.
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
[VIRTUAL] Impacts of Different EML4-ALK Variants on the Efficacy of ALK Inhibitors in ALK Positive NSCLC——A Real-World Study in China. (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1562;
Conclusion Our results indicated that patients with EML4-ALK variant 3 might have unfavorable PFS with first-line Crizotinib therapy. We expected further results to explore whether Alectinib could improve this subgroup outcome.
- [VIRTUAL] Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1560;
Newly developed TKIs achieved a partial or complete CNS response in 42.9%. Conclusion Our study shows that deferring CNS RT in oncogene-driven NSCLC and CNS involvement is a valid option due to CNS metastases response to TKIs, especially to those that can penetrate the blood-brain barrier, in order to avoid side-effects derived from CNS radiation.
- Alecensa (alectinib) / Roche
[VIRTUAL] Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1559;
The most common grade 3 AEs were laboratory abnormalities(6/9,66.7%),of which was increased blood bilirubin leading to dose reduction to alectinib 300 mg twice daily. Table 1 Baseline Patient Characteristics Conclusion This study confirms the efficacy and safety of alectinib in real-world advanced ALK+ NSCLC in China, which is consistent with data reported in clinical trials.
- Alecensa (alectinib) / Roche
[VIRTUAL] Durable Complete Response to Alectinib in Second Line Setting in Patients with Poor PS with Initial NG Tube Administration () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1558;
Table 1 Baseline Patient Characteristics Conclusion This study confirms the efficacy and safety of alectinib in real-world advanced ALK+ NSCLC in China, which is consistent with data reported in clinical trials. The abstract for this presentation is currently under embargo or has not been submitted.
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
[VIRTUAL] Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1553;
As illustrated by our case, local therapies followed by maintenance crizotinib may prolong progression-free survival (PFS). After crizotinib failure and/or among patients with CNS metastatic disease, alectinib demonstrates a high response rate and longer PFS, which is also consistent with our observational findings.
- [VIRTUAL] The Safety and Toxicities of ALK -TKIs in ALK-Positive NSCLC: A Systematic Review and Pool Analysis (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1548;
Conclusion Attention should be focused on ALK inhibitor-related SAEs although ALK inhibitors have an acceptable safety profile with a low risk of treatment-related deaths. Statistically significant differences in some severe AEs among ceritinib, crizotinib alectinib and brigatinib were detected in this pool analysis.
- Alunbrig (brigatinib) / Takeda
[VIRTUAL] First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer: A Network Meta-Analysis (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1546;
Conclusion Brigatinib significantly prolonged PFS in ALK inhibitor-naïve patients with ALK-positive NSCLC compared with ceritinib, crizotinib, and chemotherapy and was at least as effective as alectinib in reducing the risk of progression, suggesting that brigatinib is an effective 1L treatment. The results also suggest strong efficacy of brigatinib in patients with CNS metastases.
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
[VIRTUAL] Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1544;
Conclusion Alectinib efficacy and safety profile in this study align with known alectinib results in post-crizotinib setting. Identification of mechanisms of resistance emerging from exposure to previous ALK inhibitor was feasible and helped selecting subsequent treatment options.
- Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
[VIRTUAL] HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1541;
Thirdly, ALK inhibitors should be recommended for advanced NSCLC harboring HIP1-ALK, and crizotinib-resistant patients could benefit from alectinib. Long follow-up and large-sample study are needed to determine the long-term prognosis.
- Alecensa (alectinib) / Roche
[VIRTUAL] A Phase II Trial of Alectinib-Refractory Non-Small-Cell Lung Cancer with EML4-ALK Fusion Genes; Okayama Lung Cancer Study Group 1405 (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1539;
Five (56%) received post-progression ALK-TKIs. Conclusion In our series, crizotinib monotherapy after progression on the first ALK-TKI alectinib therapy produced a certain efficacy with known adverse events.
- [VIRTUAL] Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1471;
Some fusions are detected at a lower frequency than previous report, which may due to the large proportion of plasma samples. The results may offer information in more effective personalized diagnosis and therapies.
- Tagrisso (osimertinib) / AstraZeneca
[VIRTUAL] ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1397;
P2
Safety will also be reported. A summary of the observed genomic landscape during enrolment will be presented.
- Tagrisso (osimertinib) / AstraZeneca, Alecensa (alectinib) / Roche
[VIRTUAL] Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI + Brain Radiation (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1384;
Similarly, in the ALK subset, there was no significant difference between time to intracranial (12.0 mo vs 21.8 mo; p=0.24), first progression (8.1 mo vs 16.7 mo; p=0.3), or time to treatment discontinuation (17.0 mo vs 28.2 mo, p=0.49).*denotes clinical trial Conclusion These results indicate that in select patients with EGFR and ALK positive NSCLC with CNS disease, it may be reasonable to initiate CNS-penetrant TKI therapy with CNS surveillance instead of CNS radiation at treatment start, though this analysis may be underpowered with limited numbers and heterogeneity of patients and treatments. Further analysis with a larger cohort may strengthen this conclusion.
- Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
[VIRTUAL] Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1339;
P2
Brigatinib demonstrated meaningful activity in ALK TKI-resistant patients regardless of the presence of secondary ALK mutations and EML4-ALK fusion status in plasma. Clinical trial information: NCT03410108.
- [VIRTUAL] Importance of Capturing the Patient Experience of Overall Symptoms and HRQoL Impact in Patients With ALK+ NSCLC (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_602;
This qualitative research provided insights into the unmet needs and patient goals for treatment, which may then be measured in a clinical trial to demonstrate treatment benefit from the patient perspective. It is important to measure what matters most to patients to improve treatment decision-making.
- [VIRTUAL] Phase II Study of TKIs as Neo(adjuvant) Therapy in Stage II–III Resectable NSCLC with ALK, ROS1, NTRK or BRAFV600 Alterations (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_450;
Secondary efficacy objectives include investigator-assessed radiographic response, pathologic complete response, disease-free survival, event-free survival, overall survival and circulating-tumor DNA clearance rate. This trial will also evaluate exploratory biomarkers pre- and post-treatment in tissue and blood and their correlation with clinical outcomes.
- ||| Enrollment open, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MyTACTIC: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (clinicaltrials.gov) - Dec 17, 2020
P2, N=200, Recruiting, Sponsor: Genentech, Inc.
This trial will also evaluate exploratory biomarkers pre- and post-treatment in tissue and blood and their correlation with clinical outcomes. Not yet recruiting --> Recruiting
- ||| Tagrisso (osimertinib) / AstraZeneca, Alecensa (alectinib) / Roche
Clinical: @drgandara @jackwest any reason to hold a targeted drug such as osimertinib or alectinib with a newly positive COVID patient? Minimally symptomatic (Twitter) - Dec 9, 2020
- |||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
FDA event: I appreciate comments about IMP150 here in 2L ALK+, though I think IMP150 role really is in 3L ALK. 2L data lorlatinib post alectinib is robust and includes an FDA approval & I do worry with IMP150 loss of CNS control relative to these next gen inhibitors https://t.co/aUTSEVrUfV (Twitter) - Dec 8, 2020
- ||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Lorlatinib here. If not available, platinum doublet chemotherapy is appropriate, particularly pemetrexed-based regimens. I would worry a little bit about losing CNS control though, and so one could make the argument to continue alectinib with chemotherapy. (Twitter) - Dec 8, 2020
- ||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
ALK kinase domain mutations are the MC mech of Acq res to ALKi of which G1202R is the most sinister one - responds only to Lorlatinib ,seen freq. post Alectinib .Hence agree with its use . But still better to know the exact mech of resistance for understanding Evolution . (Twitter) - Dec 7, 2020
- |||| Alecensa (alectinib) / Roche
Next-Generation Sequencing: Cdkn2a is a marker of aggressiveness explains short PFS with Alectinib however unsure about it role as Acqd.Res to ALKi. Do you think repeating the NGS maybe with Liq bx would give better yield ? ALK Kinase domain mutations are very well picked up on Ngs even with DNA seq . (Twitter) - Dec 7, 2020
- ||||| Alecensa (alectinib) / Roche
M 41y, sept2019, NSLCC alk + adeno IV brain mets, lung bilat nodes, bone, liver mets. 1rst line alectinib, complete resp brain mets, lung and all. PFS 11mts. Progression Lung and pericardium. Biopsy adeno and foundationOne @PatelOncology @TonyMok9 @RamalingamMD @APassaroMD (Twitter) - Dec 7, 2020
- |||| Yes, this is mentioned in the discussion of CROWN study in NEJM - off target inhibition of tropomyosin receptor kinase B in the CNS . Check the icRR- 82% with Lorlatinib w.r.t 38,28,27 % resp with alectinib, brigatinib and ensartinib . (Twitter) - Dec 2, 2020
- |||||| Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer
New trial, Real-world evidence, Real-world: SEQUIA: Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. (clinicaltrials.gov) - Nov 29, 2020
P, N=500, Not yet recruiting, Sponsor: Pfizer
- | Alecensa (alectinib) / Roche
Journal: Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: A review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors. (Pubmed Central) - Nov 25, 2020
While he consumed alcohol, he had no other traditional risk factor. To our knowledge, this is the first reported case of hypertriglyceridemia-induced acute pancreatitis related to treatment with an anaplastic lymphoma kinase inhibitor.
- || Alecensa (alectinib) / Roche
New P2 trial, Metastases: A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (clinicaltrials.gov) - Nov 24, 2020
P2, N=50, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
I'm glad this is being discussed. I think your Q is essentially rhetorical. I'd go as far as to say that any health care system still offering only crizotinib rather than alectinib or brigatinib is disdainfully shortchanging LC pt survival. We shouldn't pander to their practices. (Twitter) - Nov 21, 2020
- ||| Alecensa (alectinib) / Roche
Clinical, FDA event: Yes, but we knew from J-ALEX & then ALEX presentations long before FDA approval that alectinib was hugely superior to criz & was on its way to be SoC. IMO, it's disingenuous bordering on unethical to have conducted trial into 2019 that randomized pts to criz. They/we KNEW better. (Twitter) - Nov 20, 2020
- ||| Alecensa (alectinib) / Roche
Clinical, FDA event: This trial started before alectinib was FDA approved later that year (and I think most patients on study where alectinib wasn’t able). Agree new studies need next gen TKI as control-would you pref dealer choice with tox/QoL uninterpretable or pick Alec/brig/or lorla as control? (Twitter) - Nov 20, 2020
- ||||| Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: Intracranial complete response rate of lorlatinib in CROWN at 61% is impressive & a consideration in 1L ALK CNS+. Alectinib (45%) and brigatinib (37%) excellent choices in light of tox profile & cross trial subset analysis-depth and duration of CNS response with lorla provocative (Twitter) - Nov 20, 2020
- || Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Not that I don't agree that Alectinib is better, but just playing Devil's advocate: In the absence of OS benefit, crizotinib remains a fair comparator option in the palliative setting, wouldn't you agree? Kind of a big thing to call it unethical. (Twitter) - Nov 20, 2020
- ||||| Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: Intracranial complete response rate of lorlatinib in CROWN at 61% is impressive & a consideration in 1L ALK CNS+. Alectinib (45%) and brigatinib (37%) excellent choices in light of tox profile & cross trial subset analysis-depth and duration of CNS response with lorla provocative (Twitter) - Nov 19, 2020
- || Alecensa (alectinib) / Roche
When this trial was designed, alectinib was not SOC (Twitter) - Nov 19, 2020
- |||| Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: Yeah that’s very reasonable, lorlatinib has robust activity in 2L even post alectinib. I do wonder for patients with CNS disease (where alectinib and brigatinib also have substantial activity) if some of the data suggesting deeper cns responses with lorlatinib may influence use (Twitter) - Nov 19, 2020
- || Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
These are great results and I expect approval. But to your point, I don’t think I’ll reach for lorlatinib first. I’m very comfortable with brigatinib or alectinib in this space and lorlatinib in later lines. (Twitter) - Nov 19, 2020